Nivolumab Monotherapy Fails to Show Improved OS Compared with Bevacizumab for Recurrent Glioblastoma
Physician's Weekly,
An identical proportion of patients in both treatment groups were alive at 12 months in the CheckMate 143…
An identical proportion of patients in both treatment groups were alive at 12 months in the CheckMate 143…
Nearly 30 percent of people in the ongoing trial have survived for at least three years after they enrolled in the study; the…
A multicenter clinical trial of DCVax-L, a personalized vaccine that targets the aggressive brain cancer glioblastoma, has…
Welcome to this week’s Research Roundup. These Friday posts aim to inform our readers about the many stories that relate to…
Researchers report a clinical trial of a personalized vaccine that targets glioblastoma brain cancer has successfully improved…
If you get your biomedical breaking news from the British press, you will have heard all about a very promising vaccine…
С помощью персонализированного средства на основе собственных дендритных клеток пациентов ученым удалось увеличить среднюю продол…